{"id":"decitabine-in-combination-with-r-chop","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Decitabine is a hypomethylating agent that reverses aberrant DNA methylation in cancer cells, restoring expression of epigenetically silenced genes. R-CHOP is a standard chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) that combines immunotherapy with cytotoxic chemotherapy. The combination aims to enhance anti-tumor efficacy in lymphoid malignancies by synergizing epigenetic reactivation with direct cytotoxic effects.","oneSentence":"Decitabine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, while R-CHOP chemotherapy directly kills lymphoma cells through multiple mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:56.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphoid malignancies (likely diffuse large B-cell lymphoma or other non-Hodgkin lymphomas)"}]},"trialDetails":[{"nctId":"NCT07348575","phase":"PHASE3","title":"A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma","status":"ENROLLING_BY_INVITATION","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2024-07-01","conditions":"Lymphoma, Large-Cell, Diffuse","enrollment":80},{"nctId":"NCT06750991","phase":"PHASE2","title":"CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-31","conditions":"DLBCL","enrollment":34},{"nctId":"NCT06748521","phase":"PHASE2","title":"Dynamic CtDNA-guided Targeted Therapy in DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-31","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Decitabine in combination with R-CHOP","genericName":"Decitabine in combination with R-CHOP","companyName":"Second Affiliated Hospital of Nanchang University","companyId":"second-affiliated-hospital-of-nanchang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Decitabine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, while R-CHOP chemotherapy directly kills lymphoma cells through multiple mechanisms. Used for Lymphoid malignancies (likely diffuse large B-cell lymphoma or other non-Hodgkin lymphomas).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}